SCHEMBL18502091

SCHEMBL18502091

Cc1ccc(Oc2ccc(C(=O)NCCCN3CCC(N4CCCCC4)CC3)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.64
L3MBTL3 Q96JM7 1/20 0.64
NPSR1 Q6W5P4 1/20 0.55
HRH3 Q9Y5N1 7/20 0.55
MMP13 P45452 2/20 0.54
TMEM97 Q5BJF2 1/20 0.53
CHRM4 P08173 1/20 0.51
POLB P06746 1/20 0.49
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
SLC6A2 P23975 1/20 0.48
SLC6A4 P31645 1/20 0.48
GLA P06280 1/20 0.47
SMYD2 Q9NRG4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18502042 0.92 L3MBTL3 (0.64) L3MBTL1L3MBTL3HRH3CHRM4POLB
SCHEMBL18502027 0.91 L3MBTL3 (0.66) L3MBTL1L3MBTL3HRH3CHRM4SLC6A2
SCHEMBL18502031 0.91 L3MBTL3 (0.68) L3MBTL1L3MBTL3NPSR1HRH3TMEM97
SCHEMBL18502059 0.91 L3MBTL3 (0.58) L3MBTL1L3MBTL3NPSR1HRH3TMEM97
SCHEMBL18502044 0.90 L3MBTL3 (0.64) L3MBTL1L3MBTL3HRH3CHRM4POLB
SCHEMBL18502089 0.90 L3MBTL3 (0.64) L3MBTL1L3MBTL3HRH3TMEM97CHRM4
SCHEMBL18502043 0.90 L3MBTL1 (0.64) L3MBTL1L3MBTL3HRH3CHRM4ALDH1A1
SCHEMBL17194188 0.90 L3MBTL3 (0.67) L3MBTL1L3MBTL3HRH3TMEM97CHRM4
SCHEMBL18502090 0.89 L3MBTL1 (0.61) L3MBTL1L3MBTL3HRH3CHRM4POLB
SCHEMBL18507067 0.88 L3MBTL3 (0.62) L3MBTL1L3MBTL3HRH3CHRM4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9809602-B2 Compounds for treating viral infections INSTITUT PASTEUR KOREA (KR) 2017-11-07 US disclosed
US-20170044181-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS INSTITUT PASTEUR KOREA (KR) 2017-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044181-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS HAVCR2, MAVS, EIF2AK2 L3MBTL1 992/4885L3MBTL3 842/4885NPSR1 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.